{"pmid":32354668,"pmcid":"PMC7183284","title":"Effect of the COVID-19 Pandemic on Cancer Clinician Decision Making: Known Knowns and Known Unknowns.","text":["Effect of the COVID-19 Pandemic on Cancer Clinician Decision Making: Known Knowns and Known Unknowns.","Clin Oncol (R Coll Radiol)","Boon, I S","Au Yong, T P T","Boon, C S","32354668"],"journal":"Clin Oncol (R Coll Radiol)","authors":["Boon, I S","Au Yong, T P T","Boon, C S"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354668","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.clon.2020.04.010","topics":["Prevention"],"weight":1,"_version_":1666138495231459328,"score":9.490897,"similar":[{"pmid":32188753,"pmcid":"PMC7082143","title":"COVID-19: Knowns, Unknowns, and Questions.","text":["COVID-19: Knowns, Unknowns, and Questions.","The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2.","mSphere","Weston, Stuart","Frieman, Matthew B","32188753"],"abstract":["The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2."],"journal":"mSphere","authors":["Weston, Stuart","Frieman, Matthew B"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32188753","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1128/mSphere.00203-20","keywords":["covid-19","sars","sars-cov-2","coronavirus"],"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Transmission"],"weight":1,"_version_":1666138490571587584,"score":148.9604},{"pmid":32310242,"pmcid":"PMC7162640","title":"The Known into the Unknown: Brugada syndrome and COVID-19.","text":["The Known into the Unknown: Brugada syndrome and COVID-19.","JACC Case Rep","Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro","32310242"],"journal":"JACC Case Rep","authors":["Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32310242","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaccas.2020.04.006","keywords":["brugada syndrome","covid-19","sudden cardiac death"],"locations":["Brugada"],"topics":["Treatment"],"weight":1,"_version_":1666138491180810240,"score":140.40707},{"pmid":32447629,"title":"COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.","text":["COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.","Concern about the appropriate role of nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 speculate that NSAIDs, in particular ibuprofen, may upregulate the entry point for the virus, the angiotensin-converting enzyme (ACE) 2 receptors and increase susceptibility to the virus or worsen symptoms in existing disease. Adverse outcomes with COVID-19 have been linked to cytokine storm but the most effective way to address exaggerated inflammatory response is complex and unclear. The Expert Working Group on the Commission of Human Medicines in the UK and other organizations have stated that there is insufficient evidence to establish a link between ibuprofen and susceptibility to or exacerbation of COVID-19. NSAID use must also be categorized by whether the drugs are relatively low-dose over-the-counter oral products taken occasionally versus higher-dose or parenteral NSAIDs. Even if evidence emerged arguing for or against NSAIDs in this setting, it is unclear if this evidence would apply to all NSAIDs at all doses in all dosing regimens. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis.","Pain Ther","Pergolizzi, Joseph V Jr","Varrassi, Giustino","Magnusson, Peter","LeQuang, Jo Ann","Paladini, Antonella","Taylor, Robert","Wollmuth, Charles","Breve, Frank","Christo, Paul","32447629"],"abstract":["Concern about the appropriate role of nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 speculate that NSAIDs, in particular ibuprofen, may upregulate the entry point for the virus, the angiotensin-converting enzyme (ACE) 2 receptors and increase susceptibility to the virus or worsen symptoms in existing disease. Adverse outcomes with COVID-19 have been linked to cytokine storm but the most effective way to address exaggerated inflammatory response is complex and unclear. The Expert Working Group on the Commission of Human Medicines in the UK and other organizations have stated that there is insufficient evidence to establish a link between ibuprofen and susceptibility to or exacerbation of COVID-19. NSAID use must also be categorized by whether the drugs are relatively low-dose over-the-counter oral products taken occasionally versus higher-dose or parenteral NSAIDs. Even if evidence emerged arguing for or against NSAIDs in this setting, it is unclear if this evidence would apply to all NSAIDs at all doses in all dosing regimens. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis."],"journal":"Pain Ther","authors":["Pergolizzi, Joseph V Jr","Varrassi, Giustino","Magnusson, Peter","LeQuang, Jo Ann","Paladini, Antonella","Taylor, Robert","Wollmuth, Charles","Breve, Frank","Christo, Paul"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447629","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s40122-020-00173-5","keywords":["acetaminophen","covid-19","ibuprofen","nsaids","paracetamol","sars-ncov-2 virus"],"locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Treatment"],"weight":1,"_version_":1667698385943003136,"score":132.78267},{"pmid":32259155,"pmcid":"PMC7117791","title":"Covid 19 pandemic and gynaecological laparoscopic surgery: knowns and unknowns.","text":["Covid 19 pandemic and gynaecological laparoscopic surgery: knowns and unknowns.","The worldwide impact of COVID 19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. Urgent gynaecological and cancer procedures are continuing, and it is imperative all theatre staff are protected and risks of SARS-CoV-2 viral transmission reduced when operating on asymptomatic, suspected or confirmed COVID 19 patients. In particular, there are concerns relating to the transmission of COVID 19 during gynaecological laparoscopic surgery, arising from the potential generation of SARS-CoV-2 contaminated aerosols from CO2 leakage and the creation of smoke from the use of energy devices. The aim of this paper is to review all the up to date evidence, including experiences from China and Italy, to guide the safe management of such patients when undergoing gynaecological procedures.","Facts Views Vis Obgyn","Mallick, R","Odejinmi, F","Clark, T J","32259155"],"abstract":["The worldwide impact of COVID 19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. Urgent gynaecological and cancer procedures are continuing, and it is imperative all theatre staff are protected and risks of SARS-CoV-2 viral transmission reduced when operating on asymptomatic, suspected or confirmed COVID 19 patients. In particular, there are concerns relating to the transmission of COVID 19 during gynaecological laparoscopic surgery, arising from the potential generation of SARS-CoV-2 contaminated aerosols from CO2 leakage and the creation of smoke from the use of energy devices. The aim of this paper is to review all the up to date evidence, including experiences from China and Italy, to guide the safe management of such patients when undergoing gynaecological procedures."],"journal":"Facts Views Vis Obgyn","authors":["Mallick, R","Odejinmi, F","Clark, T J"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259155","source":"PubMed","week":"202015|Apr 06 - Apr 12","keywords":["covid 19","coronavirus","laparoscopy","surgery"],"locations":["China","Italy"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"topics":["Prevention","Transmission"],"weight":1,"_version_":1666138493098655744,"score":125.13393},{"pmid":32392332,"title":"Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics.","text":["Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics.","Different dosage regimens of hydroxychloroquine are used to manage COVID-19 patients, without information on the pharmacokinetics in this population.Blood samples (n=101) were collected from 57 COVID-19 patients for 7 days and concentrations were compared with simulated kinetic profiles.Hydroxychloroquine exposure is low and cannot be predicted by other populations.","Clin Infect Dis","Martin-Blondel, G","Ruiz, S","Murris, M","Faguer, S","Duhalde, V","Eyvrard, F","Izopet, J","Mansuy, J M","Rolland, Y","Delavigne, K","Guimbaud, R","Pugnet, G","Conil, J M","Georges, B","Delobel, P","Minville, V","Silva Sifontes, S","Concordet, D","Gandia, P","32392332"],"abstract":["Different dosage regimens of hydroxychloroquine are used to manage COVID-19 patients, without information on the pharmacokinetics in this population.Blood samples (n=101) were collected from 57 COVID-19 patients for 7 days and concentrations were compared with simulated kinetic profiles.Hydroxychloroquine exposure is low and cannot be predicted by other populations."],"journal":"Clin Infect Dis","authors":["Martin-Blondel, G","Ruiz, S","Murris, M","Faguer, S","Duhalde, V","Eyvrard, F","Izopet, J","Mansuy, J M","Rolland, Y","Delavigne, K","Guimbaud, R","Pugnet, G","Conil, J M","Georges, B","Delobel, P","Minville, V","Silva Sifontes, S","Concordet, D","Gandia, P"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392332","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/cid/ciaa558","keywords":["covid-19","dosage regimens","drug monitoring","hydroxychloroquine","population pharmacokinetic modelling"],"topics":["Treatment"],"weight":1,"_version_":1666528580093345793,"score":98.86606}]}